This study is looking at whether elinzanetant, a drug that blocks certain brain signals (neurokinin-1/neurokinin-3 receptor antagonist), can improve blood vessel health in women who have moderate to severe hot flashes related to menopause. You may be able to join if you are a woman between 40 and 65 years old, are going through or have gone through menopause, and have moderate to severe hot flashes. You also need to have certain health conditions like obesity or high triglycerides (a type of fat in the blood). The study will measure changes in your blood vessels after 12 weeks to see if elinzanetant is helpful. We don't know the current enrollment status.

Study design

This interventional study plans to enroll 80 participants. It compares elinzanetant to a placebo (an inactive substance) over 12 weeks.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Blood vessel health will be measured at 12 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.